SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetic cardiomyopathy (DCM) leads to heart failure and mortality in diabetes mellitus (DM).
• Sodium-glucose cotransporter type 2 inhibitors (SGLT2Is) are glucose-lowering drugs with observed cardiovascular benefits.
• Clinical trials like EMPA-REG and EMPRISE demonstrated SGLT2Is reduce cardiovascular events and heart failure hospitalizations in type 2 diabetes patients.

Purpose of the Study:

• To review preclinical evidence on SGLT2 inhibitors' effects on diabetic cardiomyopathy.
• To explore potential direct cardioprotective mechanisms of SGLT2 inhibitors.
• To highlight SGLT2 inhibitors as a novel strategy for preventing DCM.

Main Methods:

• Review of current literature on SGLT2 inhibitors and DCM in preclinical studies.
• Analysis of studies investigating molecular mechanisms of SGLT2 inhibitors in the heart.
• Synthesis of findings on SGLT2 inhibitors' impact on cardiac function and pathology.

Main Results:

• SGLT2 inhibitors demonstrate beneficial effects on cardiac iron homeostasis, mitochondrial function, inflammation, fibrosis, oxidative stress, and the renin-angiotensin-aldosterone system.
• These effects suggest direct cardioprotective actions independent of glucose-lowering or natriuretic effects.
• Preclinical data support SGLT2 inhibitors' potential to mitigate DCM pathology.

Conclusions:

• SGLT2 inhibitors may offer direct cardioprotection against diabetic cardiomyopathy.
• Potential mechanisms include modulation of cardiac metabolism, inflammation, and oxidative stress.
• SGLT2 inhibitors represent a promising therapeutic strategy for preventing DCM in diabetic patients.